← Back to Search

Dietary Interventions for Insulin Resistance

N/A
Recruiting
Led By Tracey McLaughlin, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 35-65
Nondiabetic
Must not have
Patients with major organ disease
Patients with history of liposuction or bariatric surgery
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-weight loss (8 weeks)
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to understand how loss of excess weight can help reduce risk of developing insulin resistance. Blood, fat and stool are monitored to measure cellular changes.

Who is the study for?
This trial is for adults aged 35-65 with a BMI of 25-35 who have maintained a stable weight and are not diabetic. It's not suitable for those with eating disorders, psychiatric conditions, high blood pressure, diabetes, history of certain weight loss surgeries, heavy alcohol use, recent significant weight change or major organ disease.
What is being tested?
The study tests how different diets (Mediterranean Low Carbohydrate Diet vs Standard Low Carbohydrate Diet vs Standard Low Fat Diet) affect the body's response to insulin over a period of 12 weeks. Participants will undergo diet interventions and regular monitoring including blood tests and radiological assessments.
What are the potential side effects?
While this trial focuses on dietary interventions which typically don't have severe side effects like drugs do, participants may experience changes in digestion or energy levels due to new diets. Individual responses to diet changes vary.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 35 and 65 years old.
Select...
I do not have diabetes.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a serious condition affecting a major organ.
Select...
I have had liposuction or bariatric surgery in the past.
Select...
I have diabetes.
Select...
I am currently taking medication for weight loss, statins, or oral steroids.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post-weight loss (8 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and post-weight loss (8 weeks) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from baseline in plasma inflammatory cytokine levels in serum samples as measured by Luminex immunoassay
Change from baseline on the 2-stage Steady State Plasma Glucose test
Change from baseline on the magnetic-resonance based measurement of intrahepatic lipid deposition
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Standard Low Carbohydrate DietExperimental Treatment1 Intervention
Assigned participants will receive instruction by a registered dietitian on a low carbohydrate diet that is high in fats found in the typical American diet. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
Group II: Mediterranean Low Carbohydrate DietExperimental Treatment1 Intervention
Assigned participants will receive instruction by a registered dietitian on a diet that is high in unsaturated fats and low in carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
Group III: Low Fat, Healthy Carbohydrate DietExperimental Treatment1 Intervention
Assigned participants will receive instruction by a registered dietitian on a low fat diet that is high in complex carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.

Find a Location

Who is running the clinical trial?

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,443 Previous Clinical Trials
4,331,017 Total Patients Enrolled
468 Trials studying Obesity
589,595 Patients Enrolled for Obesity
Stanford UniversityLead Sponsor
2,469 Previous Clinical Trials
17,501,637 Total Patients Enrolled
70 Trials studying Obesity
270,084 Patients Enrolled for Obesity
Tracey McLaughlin, MDPrincipal InvestigatorStanford University, Department of Medicine, Division of Endocrinology
8 Previous Clinical Trials
419 Total Patients Enrolled
3 Trials studying Obesity
174 Patients Enrolled for Obesity

Media Library

Dietary Intervention Mediterranean Low Carbohydrate Diet Clinical Trial Eligibility Overview. Trial Name: NCT05165706 — N/A
Obesity Research Study Groups: Low Fat, Healthy Carbohydrate Diet, Mediterranean Low Carbohydrate Diet, Standard Low Carbohydrate Diet
Obesity Clinical Trial 2023: Dietary Intervention Mediterranean Low Carbohydrate Diet Highlights & Side Effects. Trial Name: NCT05165706 — N/A
Dietary Intervention Mediterranean Low Carbohydrate Diet 2023 Treatment Timeline for Medical Study. Trial Name: NCT05165706 — N/A
~16 spots leftby Nov 2025